-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on WAVE Life Sciences, Raises Price Target to $33

Benzinga·12/12/2025 12:40:22
Listen to the news
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and raises the price target from $20 to $33.